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RESULTS: The average VAS value at baseline was 0.65
(SD = 0.19), 0.83 (SD = 0.14) at the end of the study 
and the average change score from baseline to end of
study for the VAS was 0.17 (SD = 0.20). The differences
between the VAS value and the derived preferences
ranged from -0.07 to 0.02 at baseline. Three of the ﬁve
95% conﬁdence intervals (CIs) for the difference between
derived preferences and VAS values at baseline included
zero. At the end of the study the mean of the VAS was
higher than the means for all of the derived preference
methods. The difference between the averages for the VAS
and the derived preferences ranged from 0.01 to 0.11 and
only one of the 95% CIs for the difference included zero.
The change scores for the VAS preferences were greater
than the derived preferences (Differences from 0.07 to
0.13). None of the 95% CIs for the difference in change
scores between VAS preferences and derived preferences
crosses zero.
CONCLUSIONS: The derivation methods produce valid
and responsive measures of patient preference. However,
the derived preference values differ from each other and
directly elicited preference values. Differences in the 
distributions of the directly elicited and derived prefer-
ences will affect inferences and can lead to differing 
conclusions in a cost-utility analysis.
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OBJECTIVE: To conduct a cost-effectiveness analysis,
from the perspectives of the German and French health-
care systems, of sequential IV/PO moxiﬂoxacin (MXF)
monotherapy versus standard comparators in hospital-
ized patients with community-acquired pneumonia (CAP)
requiring parenteral treatment. 
METHODS: Costs and consequences over 21 days 
were evaluated based on clinical cure rates 5–7 days 
post-treatment and resource use reported for the 
intention-to-treat population of the TARGET multina-
tional, prospective, randomized, open-label trial. This
trial compared sequential IV/PO MXF (400mg OD) to
IV/PO amoxicillin/clavulanate (AMC) (1.2g IV/625mg
PO TID) ± clarithromycin (CLA) (500mg BID) for 7–14
days in CAP patients. Since the treatment effect on
resource use (hospital length of stay [LOS]) was similar
across countries, resource data from all 10 countries were
pooled and valued using German and French unit prices
to estimate the CAP-related cost to the German Sickness
Funds and French public healthcare sector.
RESULTS: Compared to AMC ± CLA, treatment with
MXF resulted in 5.3% more patients having clinical cure
5–7 days post-therapy (95% CI -0.1%, 12.3%), a statis-
tically signiﬁcant faster response (return to apyrexia 1 day
sooner), and reduction in LOS by 0.81 days within 
the 21-day period. Treatment with MXF resulted in per
patient savings of €266 (Germany) and €381 (France)
compared to AMC ± CLA, primarily due to a shorter
LOS. Sensitivity analyses found these results to be robust
to several costing scenarios. Using bootstrap analysis of
the trial data, the probability of MXF being cost saving
in both countries was estimated to be 95% or greater,
while the probability of MXF being cost-effective was
commensurately higher for acceptability thresholds up to
€2,000 per additional patient cured. 
CONCLUSION: MXF shows clinical beneﬁts and is 
less costly versus AMC ± CLA in the treatment of CAP.
Treatment with MXF is likely to result in cost savings 
to the German and French public healthcare systems.
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OBJECTIVES: To evaluate the psychometric charac-
teristics of the Acute Bronchitis Symptom Severity 
(ABSS) Scale, a new 7-item bronchitis-speciﬁc instrument
designed to measure outcomes in chronic bronchitis (CB)
patients. 
METHODS: Data were obtained from the screening
phase of an international clinical trial comparing the
effectiveness of moxiﬂoxacin to a standard oral anti-
biotic treatment in treating an acute exacerbation of CB. 
Subjects had a primary diagnosis of CB (having presented
with ≥2 episodes of exacerbation in the preceding year,
FEV1 < 85% of predicted value, and history of smoking),
but were not currently experiencing an acute exacerba-
tion. Patients from 19 countries completed the ABSS 
(14 languages) for 8 consecutive evenings. Psychometric
characteristics evaluated were item performance, internal
consistency reliability (Cronbach’s alpha), day-to-day
reproducibility (intraclass correlation coefﬁcient (ICC)),
construct validity (based on correlation with the St.
George’s Respiratory Questionnaire (SGRQ)), and dis-
criminant validity (based on stratiﬁcation by pulmonary
function (FEV1 % predicted)).
RESULTS: 1935 patients were enrolled. Mean age was
63.4 years (± 9.7) and 68% were male. Mean CB dura-
tion was 11.7 (± 9.6) years, with a mean of 2.9 (± 1.3)
